Anavex Life Sciences Corp (AVXL)

[georgejjl]

Last year, Tom Bishop chose Anavex (AVXL) as his Top Pick for 2021. The stock rose 235% over the past year.

Here's his latest update on the company:

After very encouraging results in a small Phase 2 study, Anavex's A2-73 Phase 2b/3 study in 500+ Alzheimer's patients was fully enrolled this spring and accordingly data from this 48-week study is due in H2 2022. The company is currently awaiting data from its second Phase 2 study in adults with Rett Syndrome at a higher dose.

The first Rett study reported surprisingly positive data given it was given to adults (with more entrenched disease) and the low dosage used in the initial study for safety reasons. The disease is so debilitating that many do not reach adulthood. A third Rett study in adolescents (the main target) is under way and due to read out in H2 2022.

Anavex is also proceeding with Parkinson's disease and Parkinson's disease dementia, with encouraging results so far and Anavex is planning its next phase trial. The consistency with which its lead compound A2-73 has reported encouragingly positive results in all of its studies so far gives added reason for optimism here, though these diseases are notoriously hard to crack.

Approval of a drug from Biogen (BGEN) — which barely worked — sets a low bar for Alzheimer's, which is a huge $10 billion market opportunity for a drug that actually works. I still maintain my "Buy" on the shares for newcomers that can accept the risks involved here.

https://www.moneyshow.com/articles/tptp2022-57945/top-picks-2022-ramaco-resources-metc/

Good luck and GOD bless,